Richardson S E, McNamara C
Department of Haematology, Royal Free Hospital, Pond Street, London NW3 2TB, UK.
Adv Hematol. 2011;2011:865870. doi: 10.1155/2011/865870. Epub 2011 Apr 6.
The management of classical Hodgkin's lymphoma (CHL) is a success story of modern multi-agent haemato-oncology. Prior to the middle of the twentieth century CHL was fatal in the majority of cases. Introduction of single agent radiotherapy (RT) demonstrated for the first time that these patients could be cured. Developments in chemotherapy including the mechlorethamine, vincristine, procarbazine and prednisolone (MOPP) and Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) regimens have resulted in cure rates of over 80%. Even in relapse, CHL patients can be salvaged with high dose chemotherapy and autologous haematopoietic stem cell transplantation (ASCT). Challenges remain, however, in finding new strategies to manage the small number of patients who continue to relapse or progress. In addition, the young age of many Hodgkin's patients forces difficult decisions in balancing the benefit of early disease control against the survival disadvantage of late toxicity. In this article we aim to summarise past trials, define the current standard of care and appraise future developments in the management of CHL.
经典型霍奇金淋巴瘤（CHL）的治疗是现代多药血液肿瘤学的成功范例。在20世纪中叶之前，大多数CHL病例都是致命的。单药放疗（RT）的引入首次证明这些患者可以治愈。化疗的发展，包括氮芥、长春新碱、丙卡巴肼和泼尼松（MOPP）以及阿霉素、博来霉素、长春花碱和达卡巴嗪（ABVD）方案，使治愈率超过了80%。即使在复发时，CHL患者也可以通过高剂量化疗和自体造血干细胞移植（ASCT）得到挽救。然而，在寻找新的策略来治疗少数持续复发或进展的患者方面，挑战依然存在。此外，许多霍奇金病患者年龄较轻，这使得在平衡早期疾病控制的益处与晚期毒性导致的生存劣势方面做出艰难决策。在本文中，我们旨在总结过去的试验，确定当前的护理标准，并评估CHL治疗的未来发展。
